10x Genomics (TXG)
(Real Time Quote from BATS)
$17.23 USD
-0.26 (-1.49%)
Updated Jul 15, 2024 02:20 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TXG 17.23 -0.26(-1.49%)
Will TXG be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TXG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TXG
10x Genomics (TXG) Surges 8.2%: Is This an Indication of Further Gains?
International Markets and 10x Genomics (TXG): A Deep Dive for Investors
TXG: What are Zacks experts saying now?
Zacks Private Portfolio Services
10x Genomics (TXG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp
3 Medical Products Stocks Set to Beat This Earnings Season
Other News for TXG
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024
Cathie Wood's ARK Investment buys 283K shares of 10x Genomics today
10x Genomics (TXG) Gets a Buy from Barclays
10x Genomics price target lowered by $12 at Barclays, here's why
Cathie Wood’s top and bottom performing ARKK holdings of H1